ABEO
Abeona Therapeutics Inc.5.0000
-0.0800-1.57%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Key Stats
Market Cap
270.96MP/E (TTM)
4.13Basic EPS (TTM)
1.21Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Abeona posted a Q3 operating loss of $24.0M, up 57% y/y from $15.3M (derived), driven by SG&A jumping to $19.3M from $6.4M on ZEVASKYN commercialization ramp-up and $0.5M cost of sales from a rejected batch due to sterility assay issues; R&D dropped 53% y/y to $4.2M as costs shifted to inventory post-FDA approval. YTD net income hit $91.6M ($1.35 diluted EPS) versus prior-year loss, fueled by $152.4M PRV sale gain, with dilutive shares expanding from 52.2M to 65.8M reconciling the basic-to-diluted EPS drop. Cash swelled to $82.9M plus $124.2M short-term investments against $19.8M debt (11.75% rate, due 2027, $5M covenant). Cash burn stings. Supply chain tariffs loom large.
8-K
ZEVASKYN launch delayed to Q4
Abeona Therapeutics reported Q3 2025 results, posting a $5.2M net loss versus $30.3M last year, with $207.5M cash funding operations over two years. ZEVASKYN's first treatments shifted to 4Q25 after fixing a false-positive sterility assay, yet demand doubled to 30 patients across three activated centers and broad payer coverage. Cash burn eased sharply.
10-Q
Q2 FY2025 results
Abeona Therapeutics swung to a $108.8M net income in Q2 FY2025 ended June 30, 2025, fueled by a $152.4M gain from selling its Priority Review Voucher, though operating loss widened 28% y/y to $22.8M amid ramped-up commercialization costs for ZEVASKYN following FDA approval. License revenue debuted at $0.4M from an AAV capsid deal, while R&D expenses dropped 36% y/y to $5.9M as pre-approval costs shifted to inventory, but SG&A surged 98% y/y to $17.1M for launch preparations. Cash swelled to $163.5M with $61.9M in short-term investments, bolstered by $17.3M from ATM equity sales, against $19.6M net debt under a $20M term loan at 13.5% interest maturing July 2027 with a $5M liquidity covenant. Diluted EPS hit $1.71 on 66.6M shares, reconciling to basic after warrant dilution. Yet regulatory hurdles could snag ZEVASKYN's rollout.
8-K
ZEVASKYN launch accelerates
Abeona Therapeutics reported Q2 2025 net income of $108.8 million, boosted by $155 million from selling its priority review voucher after FDA approval of ZEVASKYN for RDEB wounds. The therapy's U.S. launch gains traction, with first patient treatment slated for Q3 2025 amid strong demand and broad payer coverage. Cash reserves hit $226 million, funding operations over two years while eyeing profitability in H1 2026. Risks include commercialization hurdles.
8-K
Loan rate cut, warrants issued
Abeona Therapeutics amended its January 2024 loan agreement with Avenue Venture Opportunities on July 18, 2025, slashing the senior secured term loan's interest rate from 13.5% to 11.75% per annum. In exchange, it issued warrants to Avenue and Avenue 2 for 16,474 common shares at $6.07 each, expiring July 18, 2030, with cashless exercise options and change-of-control protections. This eases debt costs while diluting equity potential. Warrants carry anti-dilution safeguards.
IPO
Employees
Sector
Industry
ABCL
AbCellera Biologics Inc.
3.46-0.05
ABVC
ABVC Biopharma, Inc.
2.06-0.01
ADVM
Adverum Biotechnologies, Inc.
4.36+0.00
AEON
AEON Biopharma, Inc.
1.03+0.17
ENTO
Entero Therapeutics Inc.
2.99+0.15
IMA
ImageneBio, Inc.
6.25+0.08
KALA
KALA BIO, Inc.
0.56-0.05
KLTO
Klotho Neurosciences, Inc.
0.39+0.01
KRYS
Krystal Biotech, Inc.
238.55-4.43
LXEO
Lexeo Therapeutics, Inc.
9.73-0.03